Efficacy and safety data based on historical or pre-existing conditions at baseline for patients with active rheumatoid arthritis who were treated with baricitinib
Bernard Combe, Alejandro Balsa, Piercarlo Sarzi-Puttini, Hans-Peter Tony, Inmaculada de la Torre, Veronica Rogai, Frederick Durand, Sarah Witt, Jinglin Zhong, Maxime Dougados, Bernard Combe, Alejandro Balsa, Piercarlo Sarzi-Puttini, Hans-Peter Tony, Inmaculada de la Torre, Veronica Rogai, Frederick Durand, Sarah Witt, Jinglin Zhong, Maxime Dougados
No abstract availableKeywords: DMARDs (synthetic); rheumatoid arthritis; treatment.
Conflict of interest statement
Competing interests: BC reports grants and personal fees from Merck and Pfizer, and personal fees from AbbVie, BMS, Janssen, Eli Lilly, Roche Chugai, Sanofi and UCB, outside the submitted work. AB reports grants and personal fees from Eli Lilly, during the conduct of the study, and grants from Pfizer, AbbVie, MSD and BMS, grants and personal fees from Novartis and Nordic, and personal fees from UCB, Celltrion, Kern Pharma, Sanofi and Sandoz, outside the submitted work. H-PT reports personal fees from AbbVie, Chugai, Janssen Cilag, Eli Lilly, Novartis, Roche, Sandoz Hexal and Sanofi Aventis, outside the submitted work. MD reports grants and personal fees from Eli Lilly, Pfizer, AbbVie and UCB, during the conduct of the study. VR is a minor shareholder of Eli Lilly and Company. PSP, JZ, IdlT, FD and SW report no conflicts of interest.
References
- Dougados M, Soubrier M, Antunez A, et al. . Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis 2014;73:62–8. 10.1136/annrheumdis-2013-204223
- Keystone EC, Taylor PC, Drescher E, et al. . Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Ann Rheum Dis 2015;74:333–40. 10.1136/annrheumdis-2014-206478
- Tanaka Y, Emoto K, Cai Z, et al. . Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis receiving background methotrexate therapy: a 12-week, double-blind, randomized placebo-controlled study. J Rheumatol 2016;43:504–11. 10.3899/jrheum.150613
- INCB028050 compared to background therapy in patients with active rheumatoid arthritis (RA) with inadequate response to disease modifying anti-rheumatic drugs, 2009. Available: [Accessed 18 Mar 2018].
- Dougados M, van der Heijde D, Chen Y-C, et al. . Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis 2017;76:88–95. 10.1136/annrheumdis-2016-210094
- Taylor PC, Keystone EC, van der Heijde D, et al. . Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med 2017;376:652–62. 10.1056/NEJMoa1608345
Source: PubMed